✦ LIBER ✦

Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias

✍ Scribed by Angelo M. Carella; Ester Pungolino; Gabriella Piatti; Eugenia Gaozza; Sandro Nati; Mauro Spriano; Domenico Giordano; Tiziana D'Amico; Eugenio Damasio

Book ID: 114791089
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 345 KB
Volume: 43
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.1989.tb00304.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Single-dose mitoxantrone in combination

Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia

✍ Sung-Sook Lee; Je-Hwan Lee; Jung-Hee Lee; Dae-Young Kim; Se Hyung Kim; Sung-nam 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 146 KB

High-dose liposomal daunorubicin and hig

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

✍ Jorge Cortes; Elihu Estey; Susan O'Brien; Francis Giles; Yu Shen; Charles Koller 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Background: Liposomal encapsulation of daunorubicin (daunoxome, dnx; nexstar pharmaceutical, boulder, co) changes the pharmacology profile to increase delivery to tumor sites and decrease toxicity. the authors investigated the effect of daunorubicin in combination with ara-c in patients with ref

Efficacy and feasibility of cyclophospha

Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)

✍ Schnetzke, Ulf; Fix, Peter; Spies-Weisshart, Baerbel; Schrenk, Karin; Glaser, An 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 268 KB

A Phase I Trial of Lenalidomide in Combi

A Phase I Trial of Lenalidomide in Combination with Intermediate Dose Cytarabine (IDC) in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients

✍ Vigil, Carlos E.; Griffiths, Elizabeth A.; Thompson, James E.; Brady, William E. 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 64 KB

Idarubicin, cytarabine, and topotecan in

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome

✍ Seung Tae Lee; Joon Ho Jang; Hyung Chan Suh; Jee Sook Hahn; Yun Woong Ko; Yoo Ho 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Treatment of relapsed or refractory acut

Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine

✍ Leblanc, Thierry ;Deméocq, François ;Leverger, Guy ;Baruchel, André ;Lemerle, So 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 542 KB

## Abstract Bisantrene is an anthracene derivative which has demonstrated activity in acute myeloblastic leukemia (AML) and in lymphoma. The present study was designed to assess the reinduction rate and toxicity of bisantrene (250 mg/m^2^/d × 5) associated with aracytine (1000 mg/m^2^ twice a day ×